METHOD FOR DETERMINING AND QUANTIFYING SPECIFIC CELLULAR IMMUNITY TO SARS-CoV-2 VIRUS S-PROTEIN ANTIGENS Russian patent published in 2021 - IPC G01N33/533 G01N33/577 A61B5/145 

FIELD: medical immunology.

SUBSTANCE: invention relates to the field of medical immunology and is intended to determine and quantify the specific cellular immunity to the antigens of the S-protein of the SARS-COV-2 virus. Mononuclear cells isolated from the patient's blood are incubated in the wells of a 96-well plate, at the bottom of which the full-size S-protein is sorbed as a test sample. On a flow cytofluorometer, the percentage of a subpopulation of double-positive T-lymphocytes CD8^hiqhCD107a⁺ in the control and experimental samples is recorded. From the obtained value of the percentage of T-lymphocytes CD8^hiqhCD107a in the test sample, the value of the percentage of T-lymphocytes CD8^hiqhCD107a⁺ in the control sample is subtracted and the resulting difference in percentage is compared with the cut off value equal to 0.765%. If the obtained difference exceeds 0.765%, it is judged that the patient has specific cellular immunity to the antigens of the S-protein of the SARS-COV-2 virus in an amount equal to the obtained difference. If the obtained difference is less than 0.765%, it is judged that the patient has no specific cellular immunity.

EFFECT: invention makes it possible to quantitatively determine the cellular component of the immune defense against the SARS-COV-2 coronavirus both in those who have had COVID-19 and in vaccinated people.

1 cl, 1 dwg, 1 tbl, 1 ex